Lydall Inc (LDL) 38.03 $LDL Lydall Shares Up 37.0% Since

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Lydall Inc (LDL) 38.03 $LDL

Lydall Shares Up 37.0% Since SmarTrend's Buy Recommendation (LDL)
Comtex SmarTrend(R) - Mon Jun 13, 1:10PM CDT
SmarTrend identified an Uptrend for Lydall (NYSE:LDL) on February 23rd, 2016 at $27.73. In approximately 4 months, Lydall has returned 37.01% as of today's recent price of $37.99.
LDL: 38.03 (-0.94)

Lydall Up 36.4% Since SmarTrend Uptrend Call (LDL)
Comtex SmarTrend(R) - Fri Jun 03, 1:12PM CDT
SmarTrend identified an Uptrend for Lydall (NYSE:LDL) on February 23rd, 2016 at $27.73. In approximately 3 months, Lydall has returned 36.41% as of today's recent price of $37.82.
LDL: 38.03 (-0.94)

Shares of LDL Up 37.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri May 27, 12:40AM CDT
SmarTrend identified an Uptrend for Lydall (NYSE:LDL) on February 23rd, 2016 at $27.73. In approximately 3 months, Lydall has returned 37.82% as of today's recent price of $38.21.
LDL: 38.03 (-0.94)

Lydall Has Returned 32.7% Since SmarTrend Recommendation (LDL)
Comtex SmarTrend(R) - Thu May 19, 1:11PM CDT
SmarTrend identified an Uptrend for Lydall (NYSE:LDL) on February 23rd, 2016 at $27.73. In approximately 3 months, Lydall has returned 32.66% as of today's recent price of $36.78.
LDL: 38.03 (-0.94)

Lydall Announces Financial Results for the First Quarter Ended March 31, 2016
GlobeNewswire - Tue May 03, 3:30PM CDT
-- EPS of $0.54, up 29% from adjusted Q1 2015
LDL: 38.03 (-0.94)

Uptrend Call Working As Lydall Stock Rises 30.6% (LDL)
Comtex SmarTrend(R) - Tue Apr 26, 1:05PM CDT
SmarTrend identified an Uptrend for Lydall (NYSE:LDL) on February 23rd, 2016 at $27.73. In approximately 2 months, Lydall has returned 30.57% as of today's recent price of $36.20.
LDL: 38.03 (-0.94)

Lydall First Quarter Ended March 31, 2016 Earnings Release Conference Call Scheduled for May 4, 2016
GlobeNewswire - Tue Apr 19, 3:30PM CDT
Lydall, Inc. (NYSE:LDL) announced today that it will release its financial results for the first quarter ended March 31, 2016 on Tuesday, May 3, 2016 after the market closes. A conference call will be held on Wednesday, May 4, 2016 at 10:00 a.m. Eastern Time and be hosted by:
LDL: 38.03 (-0.94)

Lydall Up 27.6% Since SmarTrend Uptrend Call (LDL)
Comtex SmarTrend(R) - Tue Apr 19, 12:50AM CDT
SmarTrend identified an Uptrend for Lydall (NYSE:LDL) on February 23rd, 2016 at $27.73. In approximately 2 months, Lydall has returned 27.61% as of today's recent price of $35.38.
LDL: 38.03 (-0.94)

21.7% Return Seen to Date on SmarTrend Lydall Call (LDL)
Comtex SmarTrend(R) - Tue Apr 12, 12:18AM CDT
SmarTrend identified an Uptrend for Lydall (NYSE:LDL) on February 23rd, 2016 at $27.73. In approximately 2 months, Lydall has returned 21.73% as of today's recent price of $33.75.
LDL: 38.03 (-0.94)

Uptrend Call Working As Lydall Stock Rises 19.7% (LDL)
Comtex SmarTrend(R) - Mon Apr 04, 1:07PM CDT
SmarTrend identified an Uptrend for Lydall (NYSE:LDL) on February 23rd, 2016 at $27.73. In approximately 1 month, Lydall has returned 19.68% as of today's recent price of $33.18.
LDL: 38.03 (-0.94)

Lydall Down 20.1% Since SmarTrend Downtrend Call (LDL)
Comtex SmarTrend(R) - Wed Feb 10, 9:41AM CST
SmarTrend identified a Downtrend for Lydall (NYSE:LDL) on January 5th, 2016 at $33.00. In approximately 1 month, Lydall has returned 20.11% as of today's recent price of $26.36.
LDL: 38.03 (-0.94)

Lydall Shares Down 17.0% Since SmarTrend's Sell Call (LDL)
Comtex SmarTrend(R) - Tue Feb 02, 3:28PM CST
SmarTrend identified a Downtrend for Lydall (NYSE:LDL) on January 5th, 2016 at $33.00. In approximately 4 weeks, Lydall has returned 16.96% as of today's recent price of $27.40.
LDL: 38.03 (-0.94)

Shares of LDL Down 17.0% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 02, 2:16PM CST
SmarTrend identified a Downtrend for Lydall (NYSE:LDL) on January 5th, 2016 at $33.00. In approximately 4 weeks, Lydall has returned 16.96% as of today's recent price of $27.40.
LDL: 38.03 (-0.94)

Uptrend Call Working As Lydall Stock Rises 27.0% (LDL)
Comtex SmarTrend(R) - Mon Nov 23, 3:49PM CST
SmarTrend identified an Uptrend for Lydall (NYSE:LDL) on September 15th, 2015 at $28.02. In approximately 2 months, Lydall has returned 27.03% as of today's recent price of $35.60.
LDL: 38.03 (-0.94)

Lydall Has Returned 28.4% Since SmarTrend Recommendation (LDL)
Comtex SmarTrend(R) - Mon Nov 09, 9:28AM CST
SmarTrend identified an Uptrend for Lydall (NYSE:LDL) on September 15th, 2015 at $28.02. In approximately 2 months, Lydall has returned 28.41% as of today's recent price of $35.98.
LDL: 38.03 (-0.94)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Voter Events by Valley Community Healthcare Aim to Empower

Updated Category News Views 59

Here's a game-changer for the community. Valley Community Healthcare (VCH) is stepping up, proving that healthcare doesn't just stick to check-ups and prescriptions. It's about the whole shebang—community empowerment included. This October, VCH is hosting two incredible voter events, collaborating with the Los Angeles County Registrar-Recorder's Mobile Voting Program....

Continue Reading
AEVEX Facing Class Action Deadline Amid Stock Turmoil

Updated Category News Views 60

Investors are no strangers to the rough and tumble of stock markets, but things get downright messy when trust is shattered. That's the sorry saga unfolding with AEVEX, where shareholders are feeling the heat after a sharp nosedive in stock value. The clock is ticking to join the class action, and any AEVEX investor worth their salt should pay attention. Unraveling...

Continue Reading
LG OLED evo W6: UAE Roadshow Starts with a Bang

Updated Category News Views 72

They've done it again, folks. LG Electronics is out there kicking up a storm with their all-new OLED evo W6 True Wireless Wallpaper TV, and they're bringing the action straight to the UAE's doorsteps. Imagine taking a stroll and stumbling upon this technological marvel at some fancy spot like The Lotus Lounge at Anantara The Palm Dubai Resort. This ain't just a TV, it's a...

Continue Reading
Masimo's smartSET™ Revolutionizes Patient Monitoring

Updated Category News Views 58

Breaking Ground in Patient Monitoring Let's dive into the gritty details behind Masimo's latest FDA-nod: the smartSET™ system. This gizmo ain't your ordinary pulse oximeter; it's a next-gen hand-holder for the medical world, poised to ride the AI wave straight into the clinic. They've cracked open a new way for clinicians to peek behind the curtain of patient vitals,...

Continue Reading
Weifang's Cultural Resurgence: A Global Epigraphy Fest

Updated Category News Views 67

A Historical Meltdown into Global Recognition Welcome to the ride where ancient stones talk and cultural borders vanish. We're diving into the beating heart of Weifang, a place you're probably hearing about now because the town's hosting a packed international media tour. And, for a change, this isn't just another tourist trap; it's a cultural adrenaline shot to the arm,...

Continue Reading
Hyliion Class Action Deadline Nears for Investors

Updated Category News Views 78

Potential Shockwaves for Hyliion Investors Investors are having a showdown with Hyliion (NYSE:HYLN) these days. With the looming October 27, 2026, deadline to jump into a securities class action, it seems Hyliion's latest escapade smells worse than a fish market on a hot day. We’ve got allegations here stronger than your uncle’s morning coffee. Understanding the Legal...

Continue Reading
Innventure Faces Major Lawsuit Over Misleading Investors

Updated Category News Views 80

Missteps at Innventure: A Costly Lesson in Investor Trust The stock market is no stranger to drama, but Innventure's saga feels like a page ripped right out of a thriller novel. You’ve got accusations, alleged fabrications, and a swift drop in stock prices that’s left some investors shaking their heads. The company, nestled under the ticker NASDAQ:INV, finds itself...

Continue Reading

Top 5 Most Recently Viewed Articles

EYLEA HD® Injection Receives FDA Approval for RVO Treatment

Updated Category News Views 146

EYLEA HD® Injection: A Milestone in Treating Macular Edema First and only FDA-approved treatment for retinal vein occlusion (RVO) indicated for up to every 8-week dosing after an initial monthly regimen. Flexible Dosing Options for Enhanced Patient Care The recent FDA approval for EYLEA HD® (aflibercept) Injection 8 mg is a major advancement. This treatment is...

Continue Reading
Trifork Group's Recent Share Buyback Program Overview

Updated Category News Views 188

Overview of Trifork Group's Share Buyback Program The Trifork Group has recently initiated a significant share buyback program to enhance shareholder value and optimize its capital structure. This strategic decision underscores the company's commitment to returning value to its investors while maintaining a strong financial position. Details of the Share Buyback...

Continue Reading
Raymond James Celebrates Unmatched Milestone of 150 Quarters

Updated Category News Views 150

Remarkable Achievement in Consistent Profitability Raymond James has proudly reached a significant milestone of 150 consecutive quarters of profitability, showcasing nearly four decades of unwavering strength. This accomplishment highlights the firm’s resilience and dedication to its values. Guided by seasoned leaders including Chair Emeritus Tom James, Chair Paul...

Continue Reading
Innovative Cozy Sleeper Berth Light Designed for Truckers

Updated Category News Views 178

Introducing the Cozy Sleeper Berth Light The Cozy Sleeper Berth Light, developed by an innovative inventor, aims to transform the way truck drivers experience rest periods. This convenient lighting solution addresses the common issue of harsh lighting or total darkness that many drivers face while resting in their sleeper berths. The Invention's Unique Features The Cozy...

Continue Reading
ON Semiconductor Drives Innovation Amid Chip Market Changes

Updated Category News Views 141

ON Semiconductor's Recent Performance ON Semiconductor Corp (NASDAQ: ON) has recently experienced a boost following its latest earnings report. The company shared its fiscal third-quarter results, leading to an increase in stock value, reflecting investor confidence amidst ongoing fluctuations in the semiconductor sector. Quarterly Financial Highlights The latest figures...

Continue Reading